TWST
Twist Bioscience Corporation NASDAQ Listed Oct 31, 2018$58.58
After hrs
$56.00
-1.50%
Mkt Cap $3.6B
52w Low $23.30
82.5% of range
52w High $66.06
50d MA $51.21
200d MA $37.79
P/E (TTM)
-46.5x
EV/EBITDA
-31.4x
P/B
7.6x
Debt/Equity
0.3x
ROE
-16.8%
P/FCF
-22.3x
RSI (14)
—
ATR (14)
—
Beta
2.21
50d MA
$51.21
200d MA
$37.79
Avg Volume
1.3M
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
681 Gateway Boulevard · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 2, 2026 | AMC | -0.48 | -0.50 | -4.2% | 46.81 | -0.4% | -1.0% | +2.8% | +0.6% | +5.2% | +1.4% | — |
| Nov 14, 2025 | AMC | -0.50 | -0.45 | +10.0% | 26.87 | -0.5% | -1.5% | -3.2% | -5.3% | -3.0% | +6.3% | — |
| Aug 4, 2025 | AMC | -0.54 | -0.47 | +13.0% | 30.21 | +2.6% | -8.9% | -14.3% | -17.2% | -15.1% | -8.5% | — |
| May 5, 2025 | AMC | -0.56 | -0.66 | -17.9% | 35.93 | -1.7% | -8.9% | -8.8% | -9.2% | -14.2% | -8.3% | — |
| Feb 3, 2025 | AMC | -0.62 | -0.53 | +14.5% | 52.75 | +1.2% | -1.4% | +1.7% | +1.8% | -0.9% | -7.8% | — |
| Nov 18, 2024 | AMC | -0.71 | -0.59 | +17.4% | 41.43 | +0.7% | -0.3% | -0.8% | +0.6% | +1.9% | +12.0% | — |
| Aug 2, 2024 | AMC | -0.79 | -0.86 | -8.9% | 42.97 | -9.3% | +5.5% | +7.6% | +3.7% | +5.7% | +2.3% | — |
| May 2, 2024 | AMC | -0.84 | -0.79 | +6.0% | 32.01 | +19.6% | +28.7% | +39.6% | +34.7% | +29.3% | +35.0% | — |
| Feb 2, 2024 | AMC | -0.80 | -0.75 | +6.2% | 36.59 | -3.0% | -0.5% | +1.0% | -4.4% | -0.2% | +4.4% | — |
| Nov 17, 2023 | AMC | -0.94 | -0.81 | +13.8% | 24.01 | +3.6% | +3.0% | -1.2% | -0.8% | +2.0% | +0.2% | — |
| Aug 4, 2023 | AMC | -1.14 | -1.01 | +11.4% | 22.98 | -0.4% | +3.4% | +1.5% | -1.7% | -0.8% | -2.9% | — |
| May 5, 2023 | AMC | -1.09 | -1.06 | +2.8% | 12.89 | +0.2% | +4.0% | +4.9% | +2.5% | -1.5% | -7.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5 | Leerink Partners | Upgrade | Market Perform → Outperform | $70 | $56.19 | $58.32 | +3.8% | +0.9% | +5.9% | +4.2% | — | — |
| Apr 14 | Barclays | Maintains | Overweight → Overweight | — | $50.38 | $51.00 | +1.2% | +14.0% | +14.4% | +11.6% | +18.7% | +22.8% |
| Apr 6 | Evercore ISI | Maintains | Outperform → Outperform | — | $50.21 | $50.21 | +0.0% | +1.9% | -0.2% | +1.9% | -2.7% | -4.6% |
| Mar 30 | Guggenheim | Maintains | Buy → Buy | — | $44.53 | $45.33 | +1.8% | -2.9% | +6.7% | +11.3% | +12.8% | +14.9% |
| Feb 3 | Barclays | Maintains | Overweight → Overweight | — | $46.81 | $46.62 | -0.4% | -1.0% | +2.8% | +0.6% | +5.2% | +1.4% |
| Feb 3 | Evercore ISI | Maintains | Outperform → Outperform | — | $46.81 | $46.62 | -0.4% | -1.0% | +2.8% | +0.6% | +5.2% | +1.4% |
| Jan 26 | Guggenheim | Maintains | Buy → Buy | — | $42.94 | $42.68 | -0.6% | -1.1% | -0.8% | -2.2% | -3.2% | -4.4% |
| Jan 8 | TD Cowen | Maintains | Buy → Buy | — | $36.55 | $36.19 | -1.0% | -5.0% | -3.4% | +4.1% | +10.0% | +9.5% |
| Dec 15 | Barclays | Maintains | Overweight → Overweight | — | $30.93 | $31.78 | +2.7% | +0.5% | +0.6% | +3.9% | +3.2% | +5.1% |
| Nov 17 | Barclays | Maintains | Overweight → Overweight | — | $26.87 | $26.74 | -0.5% | -1.5% | -3.2% | -5.3% | -3.0% | +6.3% |
| Oct 7 | Evercore ISI | Maintains | Outperform → Outperform | — | $31.85 | $32.14 | +0.9% | -2.3% | +3.0% | +0.1% | -2.1% | -5.4% |
| Oct 2 | Barclays | Maintains | Overweight → Overweight | — | $29.26 | $29.44 | +0.6% | +4.9% | +6.2% | +8.9% | +6.4% | +12.1% |
| May 6 | Goldman Sachs | Maintains | Buy → Buy | — | $35.93 | $35.31 | -1.7% | -8.9% | -8.8% | -9.2% | -14.2% | -8.3% |
| May 6 | Guggenheim | Maintains | Buy → Buy | — | $35.93 | $35.31 | -1.7% | -8.9% | -8.8% | -9.2% | -14.2% | -8.3% |
| May 6 | Baird | Maintains | Outperform → Outperform | — | $35.93 | $35.31 | -1.7% | -8.9% | -8.8% | -9.2% | -14.2% | -8.3% |
| May 6 | JP Morgan | Maintains | Underweight → Underweight | — | $35.93 | $35.31 | -1.7% | -8.9% | -8.8% | -9.2% | -14.2% | -8.3% |
| Apr 10 | Barclays | Maintains | Overweight → Overweight | — | $40.27 | $37.84 | -6.0% | -9.0% | -3.5% | -1.1% | -1.9% | -4.5% |
| Feb 4 | Baird | Maintains | Outperform → Outperform | — | $52.75 | $53.39 | +1.2% | -1.4% | +1.7% | +1.8% | -0.9% | -7.8% |
| Feb 4 | JP Morgan | Maintains | Underweight → Underweight | — | $52.75 | $53.39 | +1.2% | -1.4% | +1.7% | +1.8% | -0.9% | -7.8% |
| Feb 4 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $52.75 | $53.39 | +1.2% | -1.4% | +1.7% | +1.8% | -0.9% | -7.8% |
| Nov 26 | TD Cowen | Maintains | Buy → Buy | — | $46.40 | $46.58 | +0.4% | -0.1% | +4.1% | +6.0% | +8.4% | +9.1% |
| Nov 19 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $41.43 | $41.72 | +0.7% | -0.3% | -0.8% | +0.6% | +1.9% | +12.0% |
| Nov 19 | Barclays | Maintains | Overweight → Overweight | — | $41.43 | $41.72 | +0.7% | -0.3% | -0.8% | +0.6% | +1.9% | +12.0% |
| Nov 19 | Baird | Maintains | Outperform → Outperform | — | $41.43 | $41.72 | +0.7% | -0.3% | -0.8% | +0.6% | +1.9% | +12.0% |
| Oct 17 | Leerink Partners | Maintains | Market Perform → Market Perform | — | $45.07 | $45.24 | +0.4% | +1.0% | +4.1% | +0.6% | -2.8% | -8.8% |
| Oct 1 | Evercore ISI | Maintains | Outperform → Outperform | — | $45.18 | $44.63 | -1.2% | -3.9% | -4.2% | -5.3% | -4.1% | -6.7% |
| Aug 5 | Barclays | Maintains | Overweight → Overweight | — | $42.97 | $38.99 | -9.3% | +5.5% | +7.6% | +3.7% | +5.7% | +2.3% |
| Aug 5 | Baird | Maintains | Outperform → Outperform | — | $42.97 | $38.99 | -9.3% | +5.5% | +7.6% | +3.7% | +5.7% | +2.3% |
| Aug 5 | JP Morgan | Maintains | Underweight → Underweight | — | $42.97 | $38.99 | -9.3% | +5.5% | +7.6% | +3.7% | +5.7% | +2.3% |
| Jul 9 | Goldman Sachs | Maintains | Buy → Buy | — | $48.95 | $49.13 | +0.4% | +3.2% | +4.2% | +7.2% | +9.2% | +14.7% |
| Jun 28 | Barclays | Maintains | Overweight → Overweight | — | $47.48 | $48.29 | +1.7% | +3.8% | +3.1% | -0.3% | +1.1% | +2.1% |
| Jun 13 | TD Cowen | Maintains | Buy → Buy | — | $52.44 | $52.98 | +1.0% | -0.8% | -5.0% | -6.6% | -3.6% | -7.1% |
| May 6 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $41.21 | $41.48 | +0.7% | +8.4% | +4.7% | +0.5% | +4.8% | +2.8% |
| May 3 | Baird | Maintains | Outperform → Outperform | — | $32.01 | $38.28 | +19.6% | +28.7% | +39.6% | +34.7% | +29.3% | +35.0% |
| May 3 | Evercore ISI | Maintains | Outperform → Outperform | — | $32.01 | $38.28 | +19.6% | +28.7% | +39.6% | +34.7% | +29.3% | +35.0% |
| May 3 | Barclays | Maintains | Overweight → Overweight | — | $32.01 | $38.28 | +19.6% | +28.7% | +39.6% | +34.7% | +29.3% | +35.0% |
| Apr 10 | Barclays | Maintains | Overweight → Overweight | — | $33.73 | $31.32 | -7.1% | -5.5% | -3.1% | -9.0% | -13.3% | -15.2% |
| Feb 5 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $36.59 | $35.50 | -3.0% | -0.5% | +1.0% | -4.4% | -0.2% | +4.4% |
| Jan 25 | Barclays | Maintains | Overweight → Overweight | — | $32.67 | $33.57 | +2.8% | -0.8% | -1.2% | +6.4% | +1.6% | -0.8% |
| Jan 18 | Goldman Sachs | Maintains | Buy → Buy | — | $34.84 | $35.35 | +1.5% | -2.8% | -3.6% | -0.2% | -1.3% | -6.2% |
| Jan 17 | Goldman Sachs | Upgrade | Neutral → Buy | — | $35.27 | $37.68 | +6.8% | -1.2% | -4.0% | -4.7% | -1.4% | -2.5% |
| Aug 7 | Barclays | Maintains | Overweight → Overweight | — | $22.98 | $22.89 | -0.4% | +3.4% | +1.5% | -1.7% | -0.8% | -2.9% |
| Jul 13 | Goldman Sachs | Maintains | Neutral → Neutral | — | $23.21 | $23.60 | +1.7% | +0.7% | +0.4% | +4.1% | +8.1% | +12.1% |
| May 8 | Baird | Maintains | Outperform → Outperform | — | $12.89 | $12.91 | +0.2% | +4.0% | +4.9% | +2.5% | -1.5% | -7.3% |
| May 8 | Barclays | Maintains | Overweight → Overweight | — | $12.89 | $12.91 | +0.2% | +4.0% | +4.9% | +2.5% | -1.5% | -7.3% |
| Apr 19 | Goldman Sachs | Maintains | Neutral → Neutral | — | $14.37 | $13.95 | -2.9% | +0.2% | -5.9% | -4.3% | -5.1% | -11.1% |
| Apr 18 | Goldman Sachs | Maintains | Neutral → Neutral | — | $14.70 | $14.80 | +0.7% | -2.2% | -2.0% | -8.0% | -6.5% | -7.3% |
| Feb 6 | Goldman Sachs | Maintains | Neutral → Neutral | — | $25.31 | $25.93 | +2.4% | -6.2% | +3.4% | +3.5% | -2.5% | -6.4% |
| Feb 6 | Barclays | Maintains | Overweight → Overweight | — | $25.31 | $25.93 | +2.4% | -6.2% | +3.4% | +3.5% | -2.5% | -6.4% |
| Feb 6 | Baird | Maintains | Outperform → Outperform | — | $25.31 | $25.93 | +2.4% | -6.2% | +3.4% | +3.5% | -2.5% | -6.4% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | WERNER ROBERT F. | Chief Accounting Officer | Sell | 164 | $57.15 | $9K | 54,635 | -1.66% | — |
| May 4, 2026 | Green Paula | SVP of Human Resources | Sell | 1,116 | $57.15 | $64K | 122,988 | -1.66% | — |
| May 4, 2026 | Leproust Emily M. | Chief Executive Officer | Sell | 5,127 | $57.15 | $293K | 853,760 | -1.66% | — |
| May 4, 2026 | Cho Dennis | See Remarks | Sell | 1,962 | $57.15 | $112K | 135,941 | -1.66% | — |
| May 4, 2026 | Finn Patrick John | President and COO | Sell | 2,844 | $57.15 | $163K | 278,964 | -1.66% | — |
| Apr 27, 2026 | Starovasnik Melissa A. | — | Sell | 500 | $61.83 | $31K | 25,222 | +3.09% | +4.99% |
| Apr 23, 2026 | Finn Patrick John | President and COO | Sell | 2,321 | $60.76 | $141K | 281,808 | -3.03% | -7.89% |
8-K · 2.02
!! High
Twist Bioscience Corporation -- 8-K 2.02: Earnings Results
Twist Bioscience released Q1 2026 earnings results, providing investors with updated financial performance and operational metrics for the quarter ended March 31, 2026.
May 4
8-K · 8.01
!! High
Twist Bioscience Corporation -- 8-K 8.01: Material Event / Announcement
Twist Bioscience secured investor commitments with registration rights agreements, enabling shareholders to liquidate holdings through registered public offerings, reducing lock-up restrictions.
Feb 17
8-K
Twist Bioscience Corporation -- 8-K Filing
I cannot provide a meaningful analysis from this filing summary, as it contains only technical metadata and schema references without substantive business information.
Feb 6
8-K
Twist Bioscience Corporation -- 8-K Filing
Twist Bioscience exceeded expectations with record $103.7M quarterly revenue, 17% year-over-year growth, and raised full-year guidance to $435-440M, signaling strong momentum in synthetic biology markets.
Feb 2
Data updated apr 27, 2026 6:13am
· Source: massive.com